Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1–9 V) during Stage 1 sacral neuromodulation
- 10 April 2018
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 122 (3) , 472-479
Abstract
Objective: To assess whether the utilisation of a motor response of 4 V in patients with overactive bladder ( OAB ) or urinary retention symptoms. Patients and Methods: An observational, retrospective, double cohort review was conducted of 339 female patients who had experienced medically recalcitrant OAB or urinary retention symptoms. Between September 2001 and September 2014, both cohorts underwent successful Stage 1 to Stage 2 SNM placement. Group A, included 174 women with a motor response at ≤3 V; and Group B, evaluated 110 women with a motor response at ≥4 V for medically recalcitrant OAB . Group C, compared 33 women with a motor response at ≤3 V; and Group D, documented 22 women with a motor response at ≥4 V for non‐obstructive urinary retention. Patients completed 3‐day voiding diaries, the Urogenital Distress Inventory‐6 ( UDI ‐6), Incontinence Impact Questionnaire‐7 ( IIQ ‐7), and Patient Global Impression of Improvement Questionnaire. Results: The mean ( sd ) follow‐up was 116.3 (30.3) months in Group A and 112 (34.6) months in Group B ( P < 0.354); 150.5 (20.4) months in Group C and 145.8 (17.2) months in Group D ( P < 0.38). Successful conversion of Stage 1 to Stage 2 showed statistically significant improvement for both P < 0.001). Group C had a 94% (34/36) conversion rate vs 70% (21/30) in Group D ( P < 0.017). Defined as a ≥50% reduction in frequency, urgency, urgency incontinence and nocturia, and UDI ‐6 and IIQ ‐7 scores, the success rate for Group A was 82.1% (143/174) and for Group B was 63% (69/110) ( P < 0.001). The mean battery life improved in both P < 0.001). Annual reprogramming sessions were reduced in Group A and Group C ( P < 0.001). Subset analysis of variance showed no statistical improvement in most patient outcomes when 1‐V subjects were compared to 2‐ and 3‐V cohorts. However, 32% of 1‐V patients ( P < 0.001) noted the onset of severe pelvic/perirectal pain and big toe plantar flexion movement with small increments in voltage (0.1–0.2 V) during reprogramming. Only 7% of 2‐V and 1% of 3‐V patients experienced this complication. Conclusions: Significant improvement was noted (up to 40%) in most clinical voiding parameters in the <3‐V patients for both OAB and urinary retention. While <3 V will still statistically improve patient outcomes, a voltage <2 V may elicit self‐reprogramming pain with severe bellows and plantar flexion movement, which may discourage patients from therapy adjustments. We recommend randomised, controlled trials to confirm these results.Keywords
This publication has 18 references indexed in Scilit:
- Successful bilateral pudendal neuromodulation to treat male detrusor areflexia following severe pubic symphysis fracture, a case reportBMC Urology, 2015
- MP89-12 DOES A LOWER VOLTAGE ATTAINED FOR GOOD BELLOWS AND IPSILATERAL PLANTAR FLEXION WITH TINED LEAD PLACEMENT PORTEND A BETTER OUTCOME FOR OVERACTIVE BLADDER SYMPTOMS WITH SACRAL NEUROMODULATION?Journal of Urology, 2015
- Long‐term follow‐up of sacral neuromodulation for lower urinary tract dysfunctionBJU International, 2014
- Neuromodulation for overactive bladderNature Reviews Urology, 2013
- Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX studyBJOG: An International Journal of Obstetrics & Gynaecology, 2012
- Chronic pudendal neuromodulation: Expanding available treatment options for refractory urologic symptomsNeurourology and Urodynamics, 2010
- Latest Technologic and Surgical Developments in Using InterStim™ Therapy for Sacral Neuromodulation: Impact on Treatment Success and SafetyEuropean Urology, 2008
- Sacral nerve stimulation for voiding dysfunction: One institution's 11‐year experienceNeurourology and Urodynamics, 2006
- New Sacral Neuromodulation Lead for Percutaneous Implantation Using Local Anesthesia: Description and First ExperienceJournal of Urology, 2003
- Improving neuromodulation technique for refractory voiding dysfunctions: Two-stage implantUrology, 1997